Here's Why Grail Stock Surged 55% This Week
Key PointsGrail's stock surged 55% after a favorable FDA committee vote, and ultimately, FDA approval could drive insurer adoption and broader market access.
Grail, a company developing a multi-cancer early detection (MCED) test, experienced a 55% surge in stock price this week following a favorable vote by the Food and Drug Administration (FDA). This approval opens the door for the FDA to grant premarket approval to Grail's Galleri MCED test, potentially leading to increased adoption by medical institutions and insurers.
During a crucial meeting of the FDA's Medical Devices Advisory Committee, the Molecular and Clinical Genetics Devices Panel voted unanimously on the safety of Galleri. The panel decided that the benefits of Galleri outweigh its risks, with a decisive six-to-four vote in favor of its effectiveness. This positive vote increases the likelihood of pre-market approval for Galleri and may prompt discussions with medical insurers who may not have considered the test without FDA approval.
However, despite the positive vote, the Galleri test failed to meet its primary objective of demonstrating a statistically significant reduction in late-stage cancer detection during a three-year study involving 142,250 patients in England's National Health Service.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
